In May, the FTC and six states filed suit to block the merger of biopharmaceutical manufacturers Amgen, Inc. and Horizon Therapeutics plc. Plaintiffs alleged that the combined entity would bundle Amgen's blockbuster drugs with Horizon's drugs in rebate contracts to effectively exclude future competitors to Horizon's products. The litigation was ultimately settled in September with a behavioral remedy. The panel, consisting of counsel on both sides and an economist involved in the litigation, will discuss the allegations, the litigation, and the settlement.
The content of this program does not meet requirements for continuing legal education (CLE) accreditation. You will not receive CLE credit for participating.
